Brussels — Aspen Pharmacare faces a EU antitrust investigation for ramping up the price of cancer drugs as the EU joins a global crackdown on the soaring cost of life-saving generic medicines. "When the price of a drug suddenly goes up by several hundred percent, this is something the commission may look at," EU competition commissioner Margrethe Vestager said in an e-mailed statement on Monday. The EU’s first investigation into so-called excessive pricing of medicines follows Italian and British action against pharmaceutical price increases. US officials have been looking at the pricing of generic medicines for more than two years, triggering civil lawsuits from customers who say they were overcharged. The EU can impose fines of as much as 10% of a company’s annual revenue. The prices of more than a dozen generic cancer treatments more than doubled between 2011 and 2016 in the UK, even as the country’s National Health Service (NHS) took aim at expensive new targeted tumour drugs. S...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now